SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
| Autor: | Ayelet Keren-Naus, Yael Raviv, Yara Khalaila, Yonat Shemer-Avni, Alona Kuzmina, Elli Rosenberg, Liora Boehm-Cohen, Ran Taube, Olga Voloshin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
COVID-19 Vaccines
Pfizer-BTN162b2 vaccine viruses Spike UK and SA variants medicine.disease_cause Antibodies Viral Microbiology Neutralization 03 medical and health sciences 0302 clinical medicine Immune system Neutralization Tests Virology United Kingdom and South African variants medicine Potency Humans BNT162 Vaccine 030304 developmental biology Infectivity 0303 health sciences Mutation biology SARS-CoV-2 Brief Report Vaccination neutralization antibodies COVID-19 Convalescence Antibodies Neutralizing Titer Spike Glycoprotein Coronavirus biology.protein Parasitology Antibody 030217 neurology & neurosurgery |
| Zdroj: | Cell Host & Microbe |
| ISSN: | 1934-6069 1931-3128 |
| Popis: | Toward eradicating the COVID-19 pandemic, vaccines that induce high humoral and cellular immune responses are essential. However, SARS-CoV-2 variants have begun to emerge and raise concerns, as they may potentially compromise vaccine efficiency. Here, we monitored neutralization potency of convalescent or Pfizer-BTN162b2 post-vaccination sera against pseudoviruses displaying spike proteins derived from wild-type SARS-CoV-2, or its UK-B.1.1.7 and SA-B.1.351 variants. Compared to convalescent sera, vaccination induces high titers of neutralizing antibodies, which exhibit efficient neutralization potential against pseudovirus carrying wild-type SARS-CoV-2. However, while wild-type and UK-N501Y pseudoviruses were similarly neutralized, those displaying SA-N501Y/K417N/E484K spike mutations moderately resist neutralization. Contribution of single or combined spike mutations to neutralization and infectivity were monitored, highlighting mechanisms by which viral infectivity and neutralization resistance are enhanced by N501Y or E484K/K417N mutations. Our study validates the importance of the Pfizer vaccine but raises concerns regarding its efficacy against specific SARS-CoV-2 circulating variants. Graphical abstract Kuzmina and colleagues monitored the neutralization potential of convalescent sera or sera from Pfizer-vaccinated individuals against pseudoviruses displaying wild-type, B.1.1.7, or B.1.351 SARS-CoV-2 spike proteins. While vaccine sera comparably neutralizes wild-type and B.1.1.7 pseudoviruses, the B.1.351 variant moderately resists vaccine-mediated neutralization, highlighting the importance of monitoring the emergence of variants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|